Editorial: New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments

Aiman Moldasheva; Vladimir Surov; Mohamad Aljofan

doi:10.3389/fphar.2022.889642

Editorial: New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments

Department of Biomedical Sciences

Nazarbayev University

Research output: Contribution to journal › Editorial › peer-review

3 Citations (Scopus)

Original language	English
Article number	889642
Journal	Frontiers in Pharmacology
Volume	13
DOIs	https://doi.org/10.3389/fphar.2022.889642
Publication status	Published - Apr 26 2022

Funding

We thank all authors, and reviewers for their contribution to this research topic, and the members of the Frontiers in Pharmacology for their continued support. This editorial is partially supported by the School of Medicine at Nazarbayev University’s SPG awarded to MA.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

anticancer
autophagy
drug repurposing, repositioning, rescue
drug screening
metformin

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.3389/fphar.2022.889642

Cite this

@article{45ea091e49eb4522ba958d0fdc1cb8d1,

title = "Editorial: New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments",

keywords = "anticancer, autophagy, drug repurposing, repositioning, rescue, drug screening, metformin",

author = "Aiman Moldasheva and Vladimir Surov and Mohamad Aljofan",

note = "Funding Information: We thank all authors, and reviewers for their contribution to this research topic, and the members of the Frontiers in Pharmacology for their continued support. This editorial is partially supported by the School of Medicine at Nazarbayev University{\textquoteright}s SPG awarded to MA.",

year = "2022",

month = apr,

day = "26",

doi = "10.3389/fphar.2022.889642",

language = "English",

volume = "13",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Editorial

T2 - New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments

AU - Moldasheva, Aiman

AU - Surov, Vladimir

AU - Aljofan, Mohamad

N1 - Funding Information: We thank all authors, and reviewers for their contribution to this research topic, and the members of the Frontiers in Pharmacology for their continued support. This editorial is partially supported by the School of Medicine at Nazarbayev University’s SPG awarded to MA.

PY - 2022/4/26

Y1 - 2022/4/26

KW - anticancer

KW - autophagy

KW - drug repurposing, repositioning, rescue

KW - drug screening

KW - metformin

UR - https://www.scopus.com/pages/publications/85129621071

UR - https://www.scopus.com/pages/publications/85129621071#tab=citedBy

U2 - 10.3389/fphar.2022.889642

DO - 10.3389/fphar.2022.889642

M3 - Editorial

AN - SCOPUS:85129621071

SN - 1663-9812

VL - 13

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 889642

ER -

Editorial: New lights Through Old Windows: Metformin and Derivatives as Anti-Cancer Treatments

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this